Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Putman

Showing results (1-10 of 59) with videos related to

Pageof 6
Sort By:
The New England Journal of Medicine|April 23, 2020
Anifrolumab in Systemic Lupus ErythematosusMichael Putman
The New England Journal of Medicine|July 10, 2023
Hospital ProblemsMichael Putman
The Lancet. Rheumatology|January 22, 2024
Interleukin-5 inhibition in eosinophilic granulomatosis with polyangiitis: time for another approach?Bonit Gill, Michael Putman
The New England Journal of Medicine|July 26, 2023
Phase 2 Trial of Peresolimab for Adults with Rheumatoid ArthritisDesh Nepal, Michael Putman
The Lancet. Rheumatology|November 8, 2024
Barriers to CAR T-cell therapy in rheumatologyKarolina Lungova, Michael Putman
Arthritis & Rheumatology (Hoboken, N.J.)|May 16, 2023
Weighing the Risks and Benefits of Pneumocystis Jirovecii Pneumonia Prophylaxis in Rituximab UsersZachary S Wallace, Michael Putman
Rheumatology (Oxford, England)|January 12, 2022
Where do we go after GiACTA?Michael Putman, Sebastian Sattui, Richard Conway
Arthritis & Rheumatology (Hoboken, N.J.)|January 9, 2025
2023 American College of Rheumatology/American College of Chest Physicians guideline for the screening and monitoring of interstitial lung disease in people with systemic autoimmune rheumatic diseases: comment on the article by Johnson et alJulian Segan, Michael Putman, Richard Conway
Rheumatic Diseases Clinics of North America|June 18, 2023
Giant Cell Arteritis and Polymyalgia Rheumatica: Treatment Approaches and New TargetsDesh Nepal, Michael Putman, Sebastian Unizony
The Lancet. Rheumatology|September 28, 2024
The emerging risk of overdiagnosis in rheumatoid arthritis and polymyalgia rheumaticaElizabeth Nettleton, Kylie Carlson, Michael Putman
Pageof 6

Showing results (1-10 of 59) with videos related to

Sort By:
Pageof 6
The New England Journal of Medicine|April 23, 2020
Anifrolumab in Systemic Lupus ErythematosusMichael Putman
The New England Journal of Medicine|July 10, 2023
Hospital ProblemsMichael Putman
The Lancet. Rheumatology|January 22, 2024
Interleukin-5 inhibition in eosinophilic granulomatosis with polyangiitis: time for another approach?Bonit Gill, Michael Putman
The New England Journal of Medicine|July 26, 2023
Phase 2 Trial of Peresolimab for Adults with Rheumatoid ArthritisDesh Nepal, Michael Putman
The Lancet. Rheumatology|November 8, 2024
Barriers to CAR T-cell therapy in rheumatologyKarolina Lungova, Michael Putman
Arthritis & Rheumatology (Hoboken, N.J.)|May 16, 2023
Weighing the Risks and Benefits of Pneumocystis Jirovecii Pneumonia Prophylaxis in Rituximab UsersZachary S Wallace, Michael Putman
Rheumatology (Oxford, England)|January 12, 2022
Where do we go after GiACTA?Michael Putman, Sebastian Sattui, Richard Conway
Arthritis & Rheumatology (Hoboken, N.J.)|January 9, 2025
2023 American College of Rheumatology/American College of Chest Physicians guideline for the screening and monitoring of interstitial lung disease in people with systemic autoimmune rheumatic diseases: comment on the article by Johnson et alJulian Segan, Michael Putman, Richard Conway
Rheumatic Diseases Clinics of North America|June 18, 2023
Giant Cell Arteritis and Polymyalgia Rheumatica: Treatment Approaches and New TargetsDesh Nepal, Michael Putman, Sebastian Unizony
The Lancet. Rheumatology|September 28, 2024
The emerging risk of overdiagnosis in rheumatoid arthritis and polymyalgia rheumaticaElizabeth Nettleton, Kylie Carlson, Michael Putman
Pageof 6